

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

- (1) POLL RESULTS OF THE 2022 ANNUAL GENERAL MEETING,
THE FIRST A SHARE CLASS MEETING OF 2023 AND
THE FIRST H SHARE CLASS MEETING OF 2023;**
- (2) RETIREMENT OF INDEPENDENT NON-EXECUTIVE
DIRECTORS;**
- (3) RE-ELECTION OF DIRECTORS AND SUPERVISORS;**
- (4) ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS;**
- (5) PAYMENT OF CASH DIVIDEND; AND**
- (6) AMENDMENTS TO ARTICLES OF ASSOCIATION**

Reference is made to (i) the circular of WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) dated April 27, 2023 (the “**Circular**”); (ii) the notice of annual general meeting dated April 27, 2023 (the “**AGM Notice**”) and the notice of the first H Share Class Meeting for 2023 dated April 27, 2023 (together with the AGM Notice, the “**Notices**”); and (iii) the announcement of the Company dated May 26, 2023 (the “**Announcement**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular, the Notices and the Announcement.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce the poll results of the 2022 annual general meeting (the “**AGM**”), the first A Share class meeting of 2023 (the “**A Share Class Meeting**”) and the first H Share class meeting of 2023 (the “**H Share Class Meeting**”, together with the AGM and the A Share Class Meeting, the “**Meetings**”) held on May 31, 2023.

For details of the resolutions considered at the Meetings, the Shareholders may refer to the Notices and the Circular.

1. CONVENING AND ATTENDANCE OF THE MEETINGS

The Meetings were convened as on-site meetings at Sheraton Shanghai Waigaoqiao Hotel, 28 Jilong Road, Pilot Free Trade Zone, Shanghai, China on Wednesday, May 31, 2023 at 2:00 p.m. Votings at the AGM and the A Share Class Meeting were taken by poll on site and online through the trading system of the Shanghai Stock Exchange (the “SSE”) and a designated voting system of the SSE by A Shareholders of the Company. Voting at the H Share Class Meeting was taken by poll on site.

Attendance of the AGM

The total number of the issued Shares of the Company as at the meeting record date was 2,967,621,532, which was the total number of Shares entitling the Shareholders to attend and vote on the resolutions proposed at the AGM. Shareholders including the Connected Selected Participants, who are also Shareholders, and their respective associates, who, to the best of the Directors’ knowledge, information and belief, owned 638,077,024 A Shares (representing approximately 21.5013% of the then issued share capital of the Company), were required to and had abstained from voting on the ordinary resolutions in respect of (i) the proposed adoption of the 2023 H Share award and Trust Scheme; (ii) the proposed grant of awards to the Connected Selected Participants under the 2023 Scheme; and (iii) the proposed authorization to the Board and/or the Delegatee to handle matters pertaining to the 2023 Scheme.

There were no Shareholders who were required to abstain from voting in favour when casting votes on any of the resolutions at the AGM according to Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) (the “**Hong Kong Listing Rules**”). There were no Shareholders, save as disclosed above, who were to abstain from voting according to the Hong Kong Listing Rules. None of the Shareholders has stated their intention in the Circular to vote against or to abstain from voting on any of the resolutions at the AGM.

A total of 386 Shareholders and authorized proxies who were entitled to vote, holding 1,405,956,727 Shares, representing approximately 47.3766% of the total number of Shares with voting rights of the Company, were present at the AGM or participated in the online voting. Among those Shareholders, 384 A Shareholders and authorized proxies, holding 1,144,041,334 A Shares, representing 38.5508% of the total number of Shares with voting rights of the Company, were present at the AGM or participated in the online voting; 2 H Shareholders and authorized proxies, holding 261,915,393 H Shares, representing 8.8258% of the total number of Shares with voting rights of the Company, were present at the AGM.

Save for Dr. Ge Li, all Directors attended the AGM.

Attendance of the A Share Class Meeting

The total number of the issued A Shares of the Company as at the meeting record date was 2,565,077,882, which was the total number of A Shares entitling the A Shareholders to attend and vote on the resolutions proposed at the A Share Class Meeting. No A Shareholders were required to abstain from voting in favour when casting votes on any of the resolutions at the A Share Class Meeting according to Rule 13.40 of the Hong Kong Listing Rules. No A Shareholders were required to abstain from voting according to the Hong Kong Listing Rules. Moreover, no A Shareholders indicated their intention to vote against or abstain from voting on the relevant resolutions contained in the Circular. A total of 384 A Shareholders with voting rights and authorized proxies, holding an aggregate of 1,144,041,334 A Shares which represented approximately 44.6006% of the total number of A Shares with voting rights, were present at the A Share Class Meeting.

Save for Dr. Ge Li, all Directors attended the A Share Class Meeting.

Attendance of the H Share Class Meeting

The total number of the issued H Shares of the Company as at the meeting record date was 402,543,650, which was the total number of H Shares entitling the H Shareholders to attend and vote on the resolutions proposed at the H Share Class Meeting. No H Shareholders were required to abstain from voting in favour when casting votes on any of the resolutions at the H Share Class Meeting according to Rule 13.40 of the Hong Kong Listing Rules. No H Shareholders were required to abstain from voting according to the Hong Kong Listing Rules. Moreover, no H Shareholders indicated their intention to vote against or abstain from voting on the relevant resolutions contained in the Circular. A total of 2 H Shareholders with voting rights and authorized proxies, holding an aggregate of 262,866,359 H Shares which represented 65.3013% of the total number of H Shares with voting rights, were present at the H Share Class Meeting.

Save for Dr. Ge Li, all Directors attended the H Share Class Meeting.

2. VOTING RESULTS OF THE MEETINGS

Voting results of the AGM

The A Shareholders and H Shareholders present at the AGM considered and approved the following resolutions by way of open poll via a combination of on-site voting and online voting, and the voting results are as follows:

| ORDINARY RESOLUTIONS# | | Number of Votes (%) | | | Approved or not |
|-----------------------|--|-----------------------------|------------------------|------------------------|-----------------|
| | | FOR | AGAINST | ABSTAIN | |
| 1. | To consider and approve the report of the Board of Directors for the year 2022. | 1,403,703,707 (99.8398%) | 1,009,579 (0.0718%) | 1,243,441 (0.0884%) | Yes |
| 2. | To consider and approve the report of the Supervisory Committee for the year 2022. | 1,403,706,107 (99.8399%) | 1,007,179 (0.0716%) | 1,243,441 (0.0885%) | Yes |
| 3. | To consider and approve the financial report for the year 2022. | 1,403,708,207 (99.8401%) | 1,006,979 (0.0716%) | 1,241,541 (0.0883%) | Yes |
| 4. | To consider and approve the proposed 2022 Profit Distribution Plan. | 1,404,863,309 (99.9222%) | 168,979 (0.0120%) | 924,439 (0.0658%) | Yes |
| 5. | To consider and approve the proposed provision of external guarantees for subsidiaries of the Company. | 1,404,567,708 (99.9012%) | 462,480 (0.0329%) | 926,539 (0.0659%) | Yes |
| 6. | To consider and approve the proposed re-appointment of Deloitte Touche Tohmatsu (a special general partnership) (德勤華永會計師事務所 (特殊普通合伙)) and Deloitte Touche Tohmatsu (德勤·關黃陳方會計師行), respectively, as PRC financial report and internal control report auditors of the Company and as offshore financial report auditors of the Company for the year 2023 and to authorize the Board to fix their remuneration. | 1,397,536,513 (99.4011%) | 7,495,575 (0.5331%) | 924,639 (0.0658%) | Yes |

| ORDINARY RESOLUTIONS [#] | | Number of Votes (%) | | | Approved or not |
|-----------------------------------|---|--|----------------------|----------------------|-----------------------|
| | | FOR | AGAINST | ABSTAIN | |
| 7. | To consider and approve the proposed foreign exchange hedging limit. | 1,404,849,509 (99.9227%) | 162,779 (0.0116%) | 924,439 (0.0657%) | Yes |
| 8. | To consider and approve the proposed re-election of executive Directors and non-executive Directors for the third session of the Board: | Resolutions below were voted by way of cumulative voting system (Number of votes) (%) | | | |
| 8.1 | to re-elect Dr. Ge Li as an executive Director. | 1,306,741,870 (92.9432%) | | | Yes |
| 8.2 | to re-elect Mr. Edward Hu as an executive Director. | 1,349,054,994 (95.9528%) | | | Yes |
| 8.3 | to re-elect Dr. Steve Qing Yang as an executive Director. | 1,354,770,204 (96.3593%) | | | Yes |
| 8.4 | to re-elect Dr. Minzhang Chen as an executive Director. | 1,351,067,556 (96.0960%) | | | Yes |
| 8.5 | to re-elect Mr. Zhaohui Zhang as an executive Director. | 1,351,183,256 (96.1042%) | | | Yes |
| 8.6 | to re-elect Dr. Ning Zhao as an executive Director. | N/A ^(Note) | | | N/A ^(Note) |
| 8.7 | to re-elect Mr. Xiaomeng Tong as a non-executive Director. | 1,309,490,512 (93.1387%) | | | Yes |
| 8.8 | to re-elect Dr. Yibing Wu as a non-executive Director. | 1,341,342,979 (95.4043%) | | | Yes |

| ORDINARY RESOLUTIONS# | | Number of Votes (%) | | | Approved or not |
|-----------------------|--|--|------------------------|----------------------|-----------------|
| | | FOR | AGAINST | ABSTAIN | |
| 9. | To consider and approve the proposed re-election and election of independent non-executive Directors for the third session of the Board: | Resolutions below were voted by way of cumulative voting system (Number of votes) (%) | | | |
| 9.1 | to re-elect Mr. Dai Feng as an independent non-executive Director. | 1,376,136,480 (97.8790%) | | | Yes |
| 9.2 | to elect Ms. Christine Shaohua Lu-Wong as an independent non-executive Director. | 1,341,819,114 (95.4382%) | | | Yes |
| 9.3 | to elect Dr. Wei Yu as an independent non-executive Director. | 1,382,304,315 (98.3177%) | | | Yes |
| 9.4 | to elect Dr. Xin Zhang as an independent non-executive Director. | 1,381,753,820 (98.2785%) | | | Yes |
| 9.5 | to elect Ms. Zhiling Zhan as an independent non-executive Director. | 1,382,395,389 (98.3242%) | | | Yes |
| 10. | To consider and approve the proposed Directors' remuneration. | 1,401,264,990 (99.6663%) | 3,738,451 (0.2659%) | 953,286 (0.0678%) | Yes |
| 11. | To consider and approve the proposal in respect of the re-election of Shareholder representative Supervisors for the third session of the Supervisory Committee: | Resolutions below were voted by way of cumulative voting system (Number of votes) (%) | | | |
| 11.1 | to re-elect Mr. Harry Liang He as a Shareholder representative Supervisor. | 1,382,835,039 (98.3554%) | | | Yes |
| 11.2 | to re-elect Mr. Baiyang Wu as a Shareholder representative Supervisor. | 1,359,217,312 (96.6756%) | | | Yes |

| ORDINARY RESOLUTIONS [#] | | Number of Votes (%) | | | Approved or not |
|--|---|-----------------------------|---------------------------|------------------------|-----------------|
| | | FOR | AGAINST | ABSTAIN | |
| 12. | To consider and approve the proposed supervisors' remuneration. | 1,404,460,425 (99.8936%) | 524,763 (0.0373%) | 971,539 (0.0691%) | Yes |
| 13. | To consider and approve the proposed adoption of the 2023 H Share Award and Trust Scheme. | 642,024,404 (83.4915%) | 126,020,799 (16.3883%) | 924,339 (0.1202%) | Yes |
| 14. | To consider and approve the proposed grant of Awards to the Connected Selected Participants under the 2023 H Share Award and Trust Scheme. | 615,457,562 (80.0367%) | 152,585,541 (19.8429%) | 926,439 (0.1204%) | Yes |
| 15. | To consider and authorize the Board and/or the Delegatee to handle matters pertaining to the 2023 H Share Award and trust Scheme with full authority. | 633,650,876 (82.4026%) | 134,392,227 (17.4769%) | 926,439 (0.1205%) | Yes |
| SPECIAL RESOLUTIONS[#] | | | | | |
| 16. | To consider and approve the proposed increase of registered capital. | 1,404,471,401 (99.8944%) | 157,945 (0.0112%) | 1,327,381 (0.0944%) | Yes |
| 17. | To consider and approve the proposed amendments to the Articles of Association. | 1,404,874,143 (99.9230%) | 158,145 (0.0112%) | 924,439 (0.0658%) | Yes |
| 18. | To consider and approve the proposed granting of general mandate to issue A Shares and/or H Shares. | 1,131,795,643 (80.5000%) | 273,002,589 (19.4176%) | 1,158,495 (0.0824%) | Yes |
| 19. | To consider and approve the proposed granting of general mandates to repurchase A Shares and/or H Shares. | 1,403,651,285 (99.8360%) | 1,146,947 (0.0816%) | 1,158,495 (0.0824%) | Yes |

Note:

As disclosed in the Announcement, the Company published an obituary mourning the passing of Dr. Ning Zhao on May 17, 2023. As such, the ordinary resolution numbered 8.6 in respect of the re-election of Dr. Ning Zhao as an executive Director as originally set out in the Circular, the AGM Notice and the accompanying proxy form was withdrawn and had not been put forward for voting at the AGM.

Voting results of the A Share Class Meeting

The A Shareholders present at the A Share Class Meeting considered and approved the following resolutions by way of open poll via on-site voting and online voting, and the voting results are as follows:

| SPECIAL RESOLUTION | | Number of Votes (%) | | | Approved or not |
|--------------------|---|-----------------------------|----------------------|------------------------|-----------------|
| | | FOR | AGAINST | ABSTAIN | |
| 1. | To consider and approve the proposed granting of general mandates to repurchase A Shares and/or H Shares. | 1,142,479,095 (99.8634%) | 544,600 (0.0476%) | 1,017,639 (0.0890%) | Yes |

Voting results of the H Share Class Meeting

The H Shareholders present at the H Share Class Meeting considered and approved the following resolutions by way of open poll via on-site voting, and the voting results are as follows:

| SPECIAL RESOLUTION [^] | | Number of Votes (%) | | | Approved or not |
|---------------------------------|---|---------------------------|----------------------|----------------------|-----------------|
| | | FOR | AGAINST | ABSTAIN | |
| 1. | To consider and approve the proposed granting of general mandates to repurchase A Shares and/or H Shares. | 262,131,467 (99.7204%) | 594,036 (0.2260%) | 140,856 (0.0536%) | Yes |

3. ATTESTATION BY LAWYERS AND SCRUTINEER

Deloitte Touche Tohmatsu served as the scrutineer at the Meetings for the purpose of vote taking.

The Meetings were attested by Fangda Partners, PRC legal advisors to the Company, which issued a legal opinion, certifying that the convening and procedures of the Meeting of the Company, the qualification of the convener, the qualification of the attendees and the voting procedures were in compliance with the relevant PRC laws and regulations and the Articles of Association of the Company. The resolutions passed at the Meetings were lawful and valid.

4. RETIREMENT OF INDEPENDENT NON-EXECUTIVE DIRECTORS

As disclosed in the announcement of the Company dated March 1, 2023, as Dr. Jiangnan Cai (蔡江南博士), Ms. Yan Liu (劉艷女士), Dr. Hetong Lou (婁賀統博士) and Mr. Xiaotong Zhang (張曉彤先生) have been serving as independent directors of the Company for almost six years, they can no longer offer themselves for re-election. As the retirement of Dr. Jiangnan Cai, Ms. Yan Liu, Dr. Hetong Lou and Mr. Xiaotong Zhang upon expiration of the term of office led to the number of independent directors and the composition of the Board falling below the requirements of the Listing Rules, the Rules Governing the Listing of Stocks on Shanghai Stock Exchange and the Articles of Association, Dr. Jiangnan Cai, Ms. Yan Liu, Dr. Hetong Lou and Mr. Xiaotong Zhang continued to act as independent non-executive Directors until the proposed re-election and proposed election of independent non-executive Directors were approved by the Shareholders at the AGM.

Each of Dr. Jiangnan Cai, Ms. Yan Liu, Dr. Hetong Lou and Mr. Xiaotong Zhang has confirmed that he or she has no disagreement with the Board and there is no other matter relating to his or her retirement that is required to be brought to the attention of the Shareholders. The Board would like to express its gratitude for the invaluable contributions of each of them to the Company during their tenure of office.

Following their respective retirement, (i) Dr. Jiangnan Cai will cease to be a member of the audit committee of the Company (the “**Audit Committee**”), a member of the strategy committee of the Company (the “**Strategy Committee**”) and the chairperson of the nomination committee of the Company (the “**Nomination Committee**”); (ii) Ms. Yan Liu will cease to be the chairperson of the remuneration and appraisal committee of the Company (the “**Remuneration and Appraisal Committee**”) and a member of the Nomination Committee; (iii) Dr. Hetong Lou will cease to be the chairperson of the Audit Committee and a member of the Remuneration and Appraisal Committee; and (iv) Mr. Xiaotong Zhang will cease to be a member of the Audit Committee.

In light of the above, the Company will be temporarily unable to meet the composition requirements of the Audit Committee, the Remuneration and Appraisal Committee as well as the Nomination Committee as set out in Rules 3.21, 3.25 and 3.27A of the Listing Rules, respectively.

The Board will elect the chairpersons and members of each of the Audit Committee, the Remuneration and Appraisal Committee, the Nomination Committee and the Strategy Committee in accordance with the requirements of Rules 3.21, 3.25 and 3.27A of the Listing Rules (where applicable) at the upcoming first meeting of the third session of the Board which is currently expected to be convened soon in early June 2023. Further announcement(s) will be made by the Company as and when appropriate.

5. RE-ELECTION OF DIRECTORS AND SUPERVISORS

Following the approval of the ordinary resolutions numbered 8.1 to 8.5, 8.7 to 8.8, 9.1 and 11.1 to 11.2 by the Shareholders at the AGM, the Board is pleased to announce that Dr. Ge Li (李革博士) (“**Dr. Li**”), Mr. Edward Hu (胡正國先生) (“**Mr. Hu**”), Dr. Steve Qing Yang (楊青博士) (“**Dr. Yang**”), Dr. Minzhang Chen (陳民章博士) (“**Dr. Chen**”) and Mr. Zhaohui Zhang (張朝暉先生) (“**Mr. Zhang**”) were re-elected as executive Directors of the third session of the Board; Mr. Xiaomeng Tong (童小蒙先生) (“**Mr. Tong**”) and Dr. Yibing Wu (吳亦兵博士) (“**Dr. Wu**”) were re-elected as non-executive Directors of the third session of the Board; Mr. Dai Feng (馮岱先生) (“**Mr. Feng**”) was re-elected as an independent non-executive Director of the third session of the Board; and Mr. Harry Liang He (賀亮先生) (“**Mr. He**”) and Mr. Baiyang Wu (吳柏楊先生) (“**Mr. Wu**”) were re-elected as Shareholders representative Supervisors of the third session of the Supervisory Committee of the Company. Mr. He, Mr. Wu, together with Ms. Minfang Zhu (朱敏芳女士) (“**Ms. Zhu**”) (re-elected as the employee representative Supervisor on May 31, 2023) are the members of the third session of the Supervisory Committee. The third session of the Board and the Supervisory Committee became effective from the conclusion of the AGM until the expiry of the third session of the Board.

For the biographical details of the re-elected executive Directors, non-executive Directors of the third session of the Board and the Shareholder representative Supervisors and employee representative Supervisor of the third session of the Supervisory Committee, please refer to the announcement and Circular of the Company dated March 20, 2023 and April 27, 2023, respectively. For the biographical details of the re-elected independent non-executive Director, please refer to the announcement and Circular of the Company dated March 1, 2023 and April 27, 2023, respectively. As at the date of this announcement, there has been no change to such information.

Save as disclosed therein, there is no other matters in relation to the re-election of Dr. Li, Mr. Hu, Dr. Yang, Dr. Chen and Mr. Zhang as executive Directors; Mr. Tong and Dr. Wu as non-executive Directors; Mr. Feng as an independent non-executive Director; Mr. He and Mr. Wu as Shareholders representative Supervisors; and Ms. Zhu as an employee representative Supervisor which would require disclosure under Rule 13.51(2) of the Hong Kong Listing Rules or matters which ought to be brought to the attention of the Shareholders.

The term of office of each of Dr. Li, Mr. Hu, Dr. Yang, Dr. Chen and Mr. Zhang as executive Directors and Mr. Tong and Dr. Wu as non-executive Directors shall be three years commencing from the approval of their election by the Shareholders at the AGM. The term of office of Mr. Feng as an independent non-executive Director will commence upon the approval by the Shareholders at the AGM and up to the end of the remainder of his consecutive six-year term as an independent director of a listed company as required by the Rules of Independent Directors of Listed Companies published by the Shanghai Stock Exchange. The term of office of each of Mr. He and Mr. Wu as Shareholder representative Supervisors and Ms. Zhu as an employee representative Supervisor shall be three years commencing from the approval of their election by the Shareholders at the AGM and at the employee meeting of the Company, respectively.

The remuneration of each of Dr. Li, Mr. Hu, Dr. Yang, Dr. Chen and Mr. Zhang as executive Directors; Mr. Tong and Dr. Wu as non-executive Directors; and Mr. Feng as independent non-executive Director shall be in line with the remuneration for the Directors for the third session of the Board as approved by the Shareholders at the AGM.

The remuneration of each of Mr. He and Mr. Wu as Shareholders representative Supervisors, and Ms. Zhu as an employee representative Supervisor shall be in line with the remuneration for the Supervisors for the third session of the Supervisory Committee of the Company as approved by the Shareholders at the AGM.

6. ELECTION OF INDEPENDENT NON-EXECUTIVE DIRECTORS

Following the approval of the ordinary resolutions numbered 9.2 to 9.5 by the Shareholders at the AGM, the Board is pleased to announce that Ms. Christine Shaohua Lu-Wong (盧韶華女士) (“**Ms. Lu-Wong**”), Dr. Wei Yu (俞衛博士) (“**Dr. Yu**”), Dr. Xin Zhang (張新博士) (“**Dr. Zhang**”), and Ms. Zhiling Zhan (詹智玲女士) (“**Ms. Zhan**”) were elected as independent non-executive Directors of the third session of the Board.

For the biographical details of the elected independent non-executive Directors, please refer to the announcement and Circular dated March 1, 2023 and April 27, 2023, respectively. As at the date of this announcement, there has been no change to such information except that a letter of appointment dated May 31, 2023 has been entered into between the Company and each of Ms. Lu-Wong, Dr. Yu, Dr. Zhang and Ms. Zhan. The term of office of each of Ms. Lu-Wong, Dr. Yu, Dr. Zhang and Ms. Zhan as independent non-executive Directors took effect from the conclusion of the AGM will end on the expiry of the third session of the Board.

Save as disclosed therein, there is no other matters in relation to the election of each of the Ms. Lu-Wong, Dr. Yu, Dr. Zhang and Ms. Zhan as independent non-executive Directors that needs to be disclosed to the Shareholders pursuant to Rule 13.51(2) of the Hong Kong Listing Rules nor is there any other matter in relation to the appointment of the abovementioned independent non-executive Directors that needs to be brought to the attention of the Shareholders.

The remuneration of each of Ms. Lu-Wong, Dr. Yu, Dr. Zhang and Ms. Zhan as independent non-executive Directors shall be in line with the remuneration for the Directors for the third session of the Board as approved by the Shareholders at the AGM.

7. PAYMENT OF CASH DIVIDEND

The Board is pleased to announce that, the Company will pay a cash dividend of RMB8.9266 (inclusive of tax) for every 10 Shares (representing an aggregate amount of RMB2,649,083,545.14 (inclusive of tax) based on the total issued share capital of the Company as at the date of this announcement) to the Shareholders whose names appear on the register of members of the Company on June 13, 2023 (the “**Record Date**”). The cash dividend will also be paid on a pro-rated basis for Shareholders who hold Shares in odd lot (i.e. RMB0.89266 per ordinary Share). The 2022 Profit Distribution will be declared according to the Articles of Association. Dividend on A Shares will be paid in Renminbi and dividend on H Shares will be paid in Hong Kong dollars. The exchange rate to be used to convert the cash dividend from RMB to HK\$ will be the average of the medium rate of RMB to HK\$ announced by the People’s

Bank of China for five working days prior to and including May 31, 2023, the date on which the 2022 Profit Distribution was declared at the AGM. The Company has appointed a receiving agent to whom the 2022 Profit Distribution will be paid for their onward payment to the H Shareholders.

The expected timetable for, among other things, the 2022 Profit Distribution as set out below is indicative only and has been prepared on the assumption that all conditions of the 2022 Profit Distribution will be fulfilled. The expected timetable is subject to change and any such change will be announced in a separate announcement by the Company as soon as practicable.

Last day of dealings in H Shares on a cum-entitlement basis. Friday, June 2, 2023

First day of dealings in H Shares on an ex-entitlement basis Monday, June 5, 2023

Latest time for lodging transfer documents of
H Shares for entitlement to the 2022 Profit Distribution. 4:30 p.m., Tuesday,
June 6, 2023

Book closure period for determining H Shareholders’
entitlement to the 2022 Profit Distribution^(Note 2) Wednesday, June 7, 2023 to
Tuesday, June 13, 2023^(Note 3)

Record date for determining H Shareholders’
entitlement to the 2022 Profit Distribution Tuesday, June 13, 2023

Register of H Shareholders of the Company reopens Wednesday, June 14, 2023

Expected date of 2022 Profit Distribution for H Shareholders . . Tuesday, June 27, 2023

Notes:

- (1) All references to time in this announcement are Hong Kong time.
- (2) If there is a tropical cyclone warning signal number 8 or above, or a black rainstorm warning:
 - (a) in force in Hong Kong at any local time before 12:00 noon but no longer in force after 12:00 noon, the latest time for lodging transfer documents will remain at 4:30 p.m. on the same Business Day;
 - (b) in force in Hong Kong at any local time between 12:00 noon and 4:30 p.m., the latest time for lodging transfer documents will be rescheduled to 4:30 p.m. on the following Business Day which does not have either of those warnings in force at any time between 9:00 a.m. and 4:30 p.m.

(3) Both days inclusive.

Details of the 2022 Profit Distribution including without limitation the expected timetable, applicable record dates, book closure arrangements, arrangements involving the Northbound Trading and Southbound Trading, applicable tax arrangements, conditions to which the 2022 Profit Distribution Plan are subject to were set out in the Circular. All Shareholders and investors are requested to read the Circular carefully and consult their advisers whenever required.

In order to determine the list of H Shareholders who are entitled to the 2022 Profit Distribution, the Company's register of H Shareholders will be closed from Wednesday, June 7, 2023 to Tuesday, June 13, 2023, both days inclusive, during which period no transfer of H Shares will be effected. H Shareholders whose names appear on the Company's register of H Shareholders on Tuesday, June 13, 2023 are entitled to receive the 2022 Profit Distribution. In order to receive the 2022 Profit Distribution, H Shareholders whose transfers have not been registered shall deposit the transfer documents together with the relevant share certificates at the H Share Registrar, Tricor Investor Services Limited, at or before 4:30 p.m. on Tuesday, June 6, 2023 at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong.

8. AMENDMENTS TO ARTICLES OF ASSOCIATION

The resolution on the amendments to the Articles of Association of the Company was approved at the AGM and will take immediate effect.

By Order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, May 31, 2023

As of the date of this announcement, the Board of the Company comprises Dr. Ge Li, Dr. Minzhang Chen, Mr. Edward Hu, Dr. Steve Qing Yang and Mr. Zhaohui Zhang as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Ms. Christine Shaohua Lu-Wong, Dr. Wei Yu, Dr. Xin Zhang, Ms. Zhiling Zhan and Mr. Dai Feng as independent non-executive Directors.

* For identification purposes only

The full text of the resolutions is set out in the notice of the AGM

^ The full text of the resolutions is set out in the notice of the H Share Class Meeting